Skip to content
The Policy VaultThe Policy Vault

Gleevec (imatinib tablets) — Medica

Melanoma, cutaneous

Initial criteria

  • age ≥ 18 years
  • Metastatic or unresectable disease
  • Activating KIT mutation
  • Tried at least one systemic regimen

Approval duration

1 year